Literature DB >> 14985563

Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis.

J Thornton1, R Elliott, M P Tully, M Dodd, A K Webb.   

Abstract

BACKGROUND: Several studies have suggested that clinical outcomes in adults with cystic fibrosis (CF) are equivalent after home and hospital treatment with intravenous antibiotics, but these studies were small and selective and only considered one course of treatment.
METHODS: A retrospective longitudinal study was performed to compare the clinical outcome over a period of 1 year of all patients attending the Manchester Adult CF Unit who received intravenous antibiotics at home or in hospital. The primary outcome measure was percentage change in forced expiratory volume in 1 second (FEV(1)) at the end of the 1 year period. Baseline "best" and "average" FEV(1) values were established for each patient for the year before the study. The secondary outcome measures were percentage changes in forced vital capacity (FVC) and body weight.
RESULTS: A total of 116 patients received 454 courses of intravenous antibiotics. At the end of 1 year there had been a mean percentage decline in FEV(1) compared with the baseline "average" for patients treated mostly at home but an improvement in patients treated mostly in hospital (Tukey's HSD mean difference 10.1%, 95% CI 2.9 to 17.2, p = 0.003). For all patients there was a mean percentage decline in FEV(1) from the baseline "best" value. For each course of treatment the mean percentage improvements in FEV(1) at the end of the course from the start of the course were significantly higher for patients treated in hospital than for those treated at home.
CONCLUSIONS: Clinical outcome, as defined by spirometric parameters and body weight, was better after a course of treatment in hospital than after home treatment, and this benefit was maintained over 1 year of treatment. The results suggest that patients treated at home need closer supervision.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985563      PMCID: PMC1746976          DOI: 10.1136/thx.2003.005876

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

Review 1.  Understanding non-compliance with treatment in adults with cystic fibrosis.

Authors:  M E Dodd; A K Webb
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  Changes in spirometry during consecutive admissions for infective pulmonary exacerbations in adolescent and adult cystic fibrosis.

Authors:  G E Packe; M E Hodson
Journal:  Respir Med       Date:  1992-01       Impact factor: 3.415

3.  An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis.

Authors:  J M Bradley; E S Wallace; J S Elborn; J L Howard; M P McCoy
Journal:  Ir J Med Sci       Date:  1999 Jan-Mar       Impact factor: 1.568

4.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

5.  Home intravenous antibiotic treatment of patients with cystic fibrosis.

Authors:  B Strandvik; L Hjelte; A S Malmborg; B Widén
Journal:  Acta Paediatr       Date:  1992-04       Impact factor: 2.299

6.  A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto.

Authors:  M Corey; F J McLaughlin; M Williams; H Levison
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

7.  Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis.

Authors:  R J Winter; R J George; S J Deacock; C D Shee; D M Geddes
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

8.  Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis.

Authors:  M N Pond; M Newport; D Joanes; S P Conway
Journal:  Eur Respir J       Date:  1994-09       Impact factor: 16.671

9.  Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease.

Authors:  M A Donati; G Guenette; H Auerbach
Journal:  J Pediatr       Date:  1987-07       Impact factor: 4.406

10.  Home intravenous antibiotic treatment in cystic fibrosis.

Authors:  J Gilbert; T Robinson; J M Littlewood
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

View more
  11 in total

1.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

2.  Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.

Authors:  D B Sanders; U Khan; S L Heltshe; M Skalland; N E West; D R VanDevanter; C H Goss; P A Flume
Journal:  J Cyst Fibros       Date:  2021-11-29       Impact factor: 5.527

3.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

4.  Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

Authors:  D R VanDevanter; P A Flume; N Morris; M W Konstan
Journal:  J Cyst Fibros       Date:  2016-04-29       Impact factor: 5.482

5.  Outcomes and Safety of Outpatient Parenteral Antimicrobial Therapy in Select Children with Cystic Fibrosis.

Authors:  Gulnur Com; Amit Agarwal; Shasha Bai; Zhuopei Hu; Grace Goode; Hollyn McCarty; Ariel Berlinski
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-12-11       Impact factor: 1.349

6.  Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit.

Authors:  E A Chrysochoou; E Hatziagorou; F Kirvassilis; J Tsanakas
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

Review 7.  C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.

Authors:  H J Longhurst; S Carr; K Khair
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

8.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

Review 9.  Home versus hospital intravenous antibiotic therapy for cystic fibrosis.

Authors:  Albert Balaguer; Javier González de Dios
Journal:  Cochrane Database Syst Rev       Date:  2015-12-15

10.  Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis.

Authors:  Leyla P Osman; Michael Roughton; Margaret E Hodson; Jennifer A Pryor
Journal:  Thorax       Date:  2009-08-23       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.